Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.
Study: Supplements slow disease progression during late stage of dry AMD
4D Molecular Therapeutics announces positive initial interim 24-week landmark data from population extension cohort of PRISM phase 2 clinical trial of 4D-150
Study suggests JAK inhibitors may reduce AMD risk in autoimmune disease patients
Study details early detection of vision loss in AMD
Approach to wet AMD treatment explores VEGF-C and VEGF-D pathways
Study zeroes in on new target for treatment of one type of macular degeneration